摘要
目的探讨血清胸苷激酶1（TK1）作为肿瘤细胞增殖标志物对恶性肿瘤诊断及疗效评估的意义。方法应用免疫印迹-增强化学发光法检测恶性肿瘤组（53例）治疗前后、体格检查组（49例）以及健康对照组（18名）的血清TK1水平。治疗前与治疗后比较用配对t检验，治疗前和后分别与健康对照组、体格检查组比较采用两独立样本均数比较t检验。结果恶性肿瘤组治疗前STK1为0．3—11．3（2．4±2．0）pmol／L；恶性肿瘤组治疗后STK1为0．3～5．0（0．9±0．8）pmol／L；体格检查组STK1为0．1～2．1（0．8±0．3）pmol／L；健康对照组STK1为0．5～1．2（0．7±0．2）pmol／L。恶性肿瘤组治疗前与治疗后之间STK1水平差异有统计学意义（t=5．257，P〈0．0001）。恶性肿瘤组治疗前与健康对照组和体格检查组STK1水平比较，差异均有统计学意义（t=3．568和5．460，P=0．001和〈0．0001），而恶性肿瘤组治疗后与健康对照组和体格检查组STK1水平比较，差异均无统计学意义（t=1．056和0．715，P均〉0．05）。结论血清TK1检测细胞增殖有较高的特异性和灵敏度，对临床监测恶性肿瘤疗效和在体格检查中进行恶性肿瘤风险筛查具有重要意义。
Objective Thymidine kinase （TK1） is an enzyme involved in DNA synthesis and hence a cell cycle dependent marker. TK1 in serum （ STK1 ） in healthy controls is rather low and increases during tumor growth. The purpose of this study was to explore the significance of STK1 as a tumor marker and its significance in the diagnosis and evaluation of treatment effect of malignancy. Methods A sensitive chemiluminescence dot-blot assay was used to measure STK1 level in 53 cases of malignant tumor patients before and after treatment, 49 cases of health-check persons and 18 healthy individuals as control group. Paired t-test was used for comparison of serum STK1 level in the tumor patients before and after treatment. Independent smples t-test was used for means comparison of serum STK1 level in the tumor patients before treatment as well as the tumor patients after treatment vs the health-check and the health control groups, respectively. Results The mean value of STK1 was 0.3 - 11.3 （2.4 ±2.0） pmol/L in tumor patients before treatment, 0.3-5.0 （0.9 ±0.8） pmol/L in tumor patients after treatment, 0.1-2.1 （0.8 ±0.3） pmol/L in the health-check group and 0.5 - 1.2 （0.7± 0.2 ） pmol/L in the control group. There was significantly higher STK1 level in the tumor patients before treatment as compared to the same group of patients after treatment （t = 5. 257, P 〈 0. 0001 ）. There was also significantly higher STK1 level in the tumor patients before treatment when compared with the health control group （ t = 3. 568, P = 0. 001 ） and the health-check group （t = 5.460, P 〈 0. 0001 ）. However, there was no statistical difference of the STK1 levels between the tumor patients after treatment and the control group （ t = 1. 056, P 〉 0.05 ） and health-check group （ t = 0. 715, P 〉 0.05）. Conclusion STK1 assay shows high sensitivity and specificity for monitoring the effectiveness of tumor treatment and may be of value in predicting the risk of malignant tumor in routine health checks.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2009年第4期271-273,共3页
Chinese Journal of Nuclear Medicine
关键词
胸苷激酶
化学发光
肿瘤
Thymidine kinase
Chemiluminescence
Neoplasms
